How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?

Abstract

Latest evidence sets a clear mandate for concurrent chemoradiotherapy as the current standard of care for inoperable stage III non small cell lung cancer patients with good performance status and minimal co-morbidities. However, a survival plateau has been reached, with disappointing results from dose escalation studies using conventional fractionation and… (More)
DOI: 10.1016/j.lungcan.2013.11.017

Topics

2 Figures and Tables

Cite this paper

@article{Bayman2014HowCW, title={How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?}, author={Neil A Bayman and Fiona Helen Blackhall and Paula McCloskey and Paul D Taylor and Corinne Faivre-Finn}, journal={Lung cancer}, year={2014}, volume={83 2}, pages={117-25} }